



IPOS 2023
WORLD CONGRESS



Survivorship and quality of life

Characteristics and components of self-management interventions for improving quality of life in cancer survivors: a systematic review

Linda Sharp

Part of the Ways Ahead study



Ways Ahead was funded by...



“An individual’s ability to manage the symptoms, treatment, physical and psychological consequences and lifestyle changes inherent in living with a chronic condition”

An ideological shift in healthcare

patients as passive recipients of care



empowered partners in managing their own health

In patients with chronic diseases, a range of benefits of self-management have been shown:

- reduction in disease symptoms
- improved psychological wellbeing
- improved quality-of-life (QoL)
- reduced (unnecessary) healthcare resource utilisation

Self-management in cancer

- Most survivors engage in multiple self-management behaviour(s)*
- Self-management part of cancer strategy in several countries
- Range of self-management interventions have been developed and tested in cancer survivors



But gaps in evidence remain, which hinder wider implementation into routine care.

e.g. *which intervention characteristics and components are beneficial?*

Aim: To systematically identify and review studies reporting self-management interventions in adult cancer survivors for:

(i) description of intervention characteristics and components, and

(ii) associations with quality-of-life (QoL)

Search


- MEDLINE, EMBASE, CINAHL, PsychInfo, Cochrane CENTRAL and Scopus
- Reference lists of published reviews & eligible papers
- Consultation with topic experts

Extraction, synthesis & appraisal

- Intervention characteristics: TIDieR framework*
- Self-management support components: PRISMS taxonomy **
- Narrative synthesis
- Quality appraisal: CASP (RCTs); JBI (before & after)

Eligibility

- Intervention described as involving self-management or building self-management skills
- Evaluated in study with comparison group (e.g. trial, before-and-after study); if trial, comparator arm must not involve self-management
- Target population must have completed hospital-based cancer treatment
- QoL reported outcome




* including protocol papers, intervention development papers, papers reporting different outcomes (eg health economics) or follow-up periods, etc

n=32

- **Country of study:** USA (n=10), UK (n=5), Netherlands (n=4), Republic of Korea (n=4), Australia (n=3), Iran (n=2), and one each in Belgium, Canada, Germany, Israel
- **Cancer(s) included:** mixed cancers (n=11, though 6 had majority breast cancers), breast (n=10), prostate (n=7), head & neck (n=2), gastric (n=1), not reported (n=1)
- **Time since treatment:** 2 months -10.5 years (18 studies); not reported in remainder
- **Design:** RCTs (n=20); historical controlled trial (n=1); prospective non-randomised trial (n=1); pre-post design (n=10). Most common external comparators were: usual care (n=10), usual care plus (n=7), wait list (n=6)
- **Sample size:** intervention group 6-320; <50 (n=18), 50-99 (n=6), 100+ (n=7), not reported (n=1)

PRISMS self-management components included in interventions





Theoretically informed: 24 interventions



How delivered:


face-to-face only: 7
face-to-face & phone: 7
face-to-face & online: 1
phone only: 4
online only: 11
unclear: 2



By whom:



health professional: 10
other professional: 6
self-administered: 11
multiple modes: 4
unclear: 1



To whom:


individual only: 12
group-based: 11
mix of individual & group: 8
unclear: 1




Tailoring:

Yes: 20
No/unclear: 12

- 20 RCTs were appraised using 6-item modified CASP RCT checklist



- 12 non-RCTs were appraised using 9-item JBI checklist for quasi-experimental studies





- QoL was assessed in all studies; primary outcome in 8
- Most studies did not clearly state what their primary outcome was
- Measured using 20 different instruments
 - EORTC QLQ-C30 n=10 studies; FACT-G (n=15); SF-36 (n=4); EPIC-26 (n=3)
 - author designed VAS (n=2)
 - multiple instruments (n=8)
- Reported at baseline and 1-3 follow-up time points, ranging from immediately to 12 months post-intervention



- **12 studies** (8 with low risk of bias) with comparator groups reported **significant between-group differences** in QoL
 - **15 studies** (6 with low risk of bias) reported **significant improvements over time** in QoL
- Overall, **22 studies reported differences/improvements** in QoL
- Some instruments used had minimally clinically important differences (MCIDs). **4 of 8 studies** which used these instruments **found MCIDs** in QoL. But these tended to be seen only for some QoL subscales within these studies.



- Assessed in 14 studies
- Measured using variety of different instruments
- 7 studies (2 with low risk of bias) found improvement in self-efficacy from baseline (pre-intervention) to follow-up
- 5 of these studies found improvements in self-efficacy over time post-intervention
- 6 of the 7 studies that reported improved self-efficacy also reported improved QoL

Study and intervention features considered in relation to whether (or not) studies found differences/improvements in QoL

- cancer site
- study design
- TIDieR characteristics
 - intervention, mode of delivery, location, tailoring, type of delivery
- PRISMS components
 - individual components, number of components included

In general, very few clear patterns were seen

How intervention delivered

- combination of individual & group delivery:
- delivered to individuals alone:

8/8 studies reported improved QoL
12/20 studies reported improved QoL

Practical support with adherence:

9/10 studies reported improved QoL

Assessed in 9 studies

Health service resource use

- 2 studies reported fewer hospital visits in intervention group*
- 1 reported shorter duration of hospitalisation**

Cost-utility analysis: assessed in 2 studies



Including health economic analysis in pilot studies: lessons learned from a cost-utility analysis within the PROSPECTIV pilot study

Richéal M. Burns¹, Jane Wolstenholme¹, Bethany Shinkins², Emma Frith³, Lauren Matheson³, Peter W. Rose⁴, Ella Watson¹

¹Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford - UK
²Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds - UK
³Faculty of Health and Life Sciences, Oxford Brookes University, Oxford - UK
⁴Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford - UK

Journal of Cancer Survivorship (2021) 15:77–86
<https://doi.org/10.1007/s11764-020-00912-9>

Cost-utility of an eHealth application 'Oncokompas' that supports cancer survivors in self-management: results of a randomised controlled trial



A. van der Hout^{1,2} · F. Jansen^{1,2,3} · C. F. van Uden-Kraan^{1,2} · V. M. Coupé⁴ · K. Holtmaat^{1,2,3} · G. A. Nieuwenhuijzen⁵ · J. A. Hardillo⁶ · R. J. Baatenburg de Jong⁶ · N. L. Tiren-Verbeet⁷ · D. W. Sommeijer^{8,9} · K. de Heer^{8,10} · C. G. Schaar¹¹ · R. J. E. Sedee¹² · K. Bosscha¹³ · M. W. M. van den Brekel¹⁴ · J. F. Petersen¹⁴ · M. Westerman¹⁵ · J. Honings¹⁶ · R. P. Takes¹⁶ · I. Houtenbos¹⁷ · W. T. van den Broek¹⁸ · R. de Bree¹⁹ · P. Jansen²⁰ · S. E. J. Eerenstein^{2,3} · C. R. Leemans² · J. M. Zijlstra^{2,21} · P. Cuijpers¹ · L. V. van de Poll-Franse^{22,23,24} · I. M. Verdonck-de Leeuw^{1,2,3}

- PROSPECTIV – intervention in men with prostate cancer
- Cost-effectiveness inconclusive

- Oncokompas – intervention for survivors with range of cancer
- 47% probability that it is more effective and less costly than usual care

- Self-management support interventions show promise for improving cancer survivors' QoL post-treatment

BUT.....

- Study quality is variable (e.g. design, sample size, risk of bias)
- There is substantial heterogeneity in characteristics and components used (and, often times, poor reporting); this means it's impossible to determine (with confidence) which intervention components or characteristics are associated with effectiveness
- Insufficient knowledge of economic consequences/cost-effectiveness

1. Self-management interventions are hard to systematically identify. Researchers should clearly describe their interventions as being self-management.
2. Most of the evidence still relates to breast cancer in women in high income settings. We need to investigate effectiveness of self-management interventions in other cancers and other settings.
3. We need larger, higher quality studies, in all settings.
4. We need to better describe our interventions and their content/active ingredients, when reporting (to enable replication).
5. Some supported self-management components have been little investigated (e.g. information about available resources). Future interventions might consider these.
6. Health economic evaluation of self-management interventions should be routine. Absence of this data likely hinders implementation.

Thank you

Ben Rimmer¹, Morven Brown¹, Tumi Sotire¹, Fiona Beyer¹, Iakov Bolnykh¹, Michelle Balla¹, Lizzie Dutton¹, Sophie Williams², Vera Araújo-Soares³, Tracy Finch⁴, Pamela Gallagher⁵, Joanne Lewis², Richéal Burns⁶, Linda Sharp¹

¹Newcastle University, ²Newcastle upon Tyne Hospitals NHS Foundation Trust, ³Heidelberg University, ⁴Northumbria University, ⁵Dublin City University, ⁶Atlantic Technological University

linda.sharp@ncl.ac.uk; ben.rimmer@ncl.ac.uk